Tariff Trouble: The Unintended Consequences of Trump’s Generic Drug Gambit

The latest salvo in President Trump’s trade wars is a proposal to impose 100% tariffs on generic drugs imported into the US, starting in 2028. This move appears to be another instance of the administration’s “America First” policy, aimed at reshoring pharmaceutical production and protecting American jobs. However, experts warn that the consequences of such a drastic measure could be far more complex – and potentially devastating for patients.

Generic drugs account for over 90% of prescriptions filled in the US, making them an essential component of the country’s healthcare system. The proposal to tax generic imports could have a ripple effect that transcends the pharmaceutical industry itself. For instance, Robin Feldman notes that generic drugs account for 90% of pharmaceutical sales in the U.S., meaning prices might remain relatively low even if they double due to tariffs.

Critics argue that high tariffs will lead to shortages of certain generic drugs in the US, as manufacturers decide to leave the American market altogether. This is particularly concerning given the country’s recent history with drug shortages and rising healthcare costs. A staggering 50% of adults say it’s hard to afford health costs, and over 40% have gone without prescribed medication due to high prices.

The generic industry will be forced to adapt – or risk losing market share – if Trump follows through on his threat. Industry leaders claim they’re committed to pursuing policies that support and stabilize both the industry and patient access to affordable medicines. However, this promise is undermined by the uncertainty surrounding Trump’s proposal.

This development mirrors past attempts by governments to control pharmaceutical costs through tariffs or regulations. The US has a long history of struggles with generic drug availability, from Canada’s efforts to limit imports in the 1990s to more recent concerns over Indian and Chinese production. Each time, the consequences have been complex and far-reaching – often resulting in unintended shortages and price increases.

Trump’s proposal seems less about reshoring pharmaceutical production than it does a bid to flex his trade muscle. Imposing massive tariffs on generic medicines risks making lower-cost drugs millions of Americans rely on more expensive and harder to access. The impact for consumers will ultimately depend on the specifics of the policy, but one thing is clear: the stakes are high, and the consequences of this move could be far-reaching.

As the country grapples with an already-strained healthcare system, proposals like these serve only to amplify existing concerns about affordability and accessibility. The administration would do well to reconsider its approach – lest it inadvertently exacerbate the very problems it purports to address. The generic drug market is a delicate ecosystem, prone to disruptions from both internal and external factors. Trump’s proposed tariffs are the latest example of how poorly calibrated trade policies can have far-reaching consequences for patients and healthcare systems worldwide.

It remains to be seen whether this move will become yet another example of the administration’s willingness to risk short-term gains for long-term stability – or if it will prove a turning point in its approach to healthcare policy.